Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: REGENXBIO

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
March 5, 2024

REGENXBIO Announces New Positive Initial Efficacy Data From Affinity Duchenne® Trial

REGENXBIO reports additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne.
Read More
February 8, 2024

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

REGENXBIO announces completion of enrollment in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202.
Read More
November 30, 2023

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

REGENXBIO announces that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial.
Read More
November 9, 2023

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

On November 9, 2023, REGENXBIO announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to...
Read More
October 6, 2023

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

Regenxbio announces interim safety data and initial efficacy data from the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne.
Read More
April 12, 2023

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne

REGENXBIO receives fast track designation for RGX-202 for the treatment of Duchenne
Read More
January 23, 2023

REGENXBIO Announces Phase I/II Trial of RGX-202 is Active and Recruiting Duchenne Patients

REGENXBIO announces Phase I/II AFFINITY DUCHENNE trial is active and recruiting patients
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*) 





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Register Now

    Experience the magic this summer!

    Apply Today

    How is the rare disease community accomplishing goals?

    Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

    Register Today

    Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

    Give Today

    Accessible Vehicle Fund Applications Open

    Apply Today